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Abstract
Immunization of BALB/c mice with radiation-attenuated Plasmodium yoelll sporozoites induces
cytotoxic T lymphocytes (CTL) specific for an epitope located within the amino acid sequence
277-288 of the P. yoelll circumsporozoite (CS) protein. Several CD8+ CTL clones were derived
from the spleen cells of sporozolte-immunlzed mice, all displaying an apparently Identical epitope
specificity. All the clones Induced high levels of cytolysls In vitro upon exposure to peptide-
Incubated MHC-compatlble target cells. The adoptive transfer of two of these clones conferred
complete protection against sporozotte challenge to naive mice. This protection Is species and
stage specific. Using P. yoelll specific rlbosomal RNA probes to monitor the In vivo effects of the
CTL clones, we found that their target was the Intrahepatocytlc stage of the parasite. The
protective clones completely Inhibited the development of the liver stages of P. yoelll. Some CTL
clones were only partially Inhibitory In vivo, while others failed completely to alter liver stage
development and to confer any detectable degree of protection. The elucidation of the effector
mechanism of this CTL mediated protection against rodent malaria should facilitate the design of
an effective malaria vaccine. From a broader perspective this model may provide further Insight
Into the mechanlsm(s) of CTL mediated killing of intracellular non-viral pathogens In general.
Introduction
Protective immunity against rodent, simian and human malaria
can be achieved by immunization with radiation-attenuated
sporozoites (1). This protection appears to be mediated by a
combination of humoral and T-cell mediated mechanisms (2,3).
The extent to which any of these individual immune mechanisms
can confer protection, in the absence of the others, remains to
be determined.
Epitopes located within the circumsporozoite (CS) protein that
are recognized by CD8+ cytolytic T lymphocytes (CTL) have
been defined for several species of Plasmodia (3 - 6). Immuniza-
tion of BALB/c mice with irradiated Plasmodium berghei
sporozoites induces CD8+ CTL which recognize a synthetic
peptide comprising amino acids 249-260 (NDDSYPSAEKI) of
its CS protein (3). Immunization with irradiated Plasmodium yoelii
sporozoites of BALB/c mice also induces CD8+ CTL, which
recognize an epitope contained in a peptide with a sequence
(P. yoelii CS 277 - 288, NEDSYVPSAEQI) highly homologous to
that of the P. berghei CTL epitope. Both of these CS peptides
are presented to T cells in the context of the major histo-
compatjbility complex (MHC) H-2 kd molecule (6). Another study
(5) defined a similar, overlapping P. yoelii CS epitope (CS
281-296).
It has been established that the adoptive transfer of cloned
CD8+ CTLs specific for the P. berghei CS epitope can confer
complete protection against sporozoite-induced infection (3).
However, it has been suggested that CD8+ T cells against the
P. yoelii CS protein may not have a similar protective role (5).
The availability of cloned CD8+ CTL, specific for the P. yoelii
cytotoxic CS epitope, did permit us to establish the broader
validity of the protective role of anti-CS CD8+ CTL in rodent
malaria and, also, determine their specificity. Using a recently
described method for measuring plasmodial ribosomal RNA
Correspondence to: F. Zavala, 341 East 25th Street New York, NY 10010, USA
Transmitting editor: Z. Ovary Received 25 February 1991, accepted 18 March 1991
580 CD8+ T cell clones protect against malaria
sequences in infected mouse liver, we evaluated quantitatively
the protective in vivo activity of the CTL clones.
Methods
Parasites and animals
Plasmodium yoelii (17X NL strain) and P. berghei (NK 65 strain)
were maintained by repeated cyclic passage of the parasites
through Anopheles stephensi mosquitoes, and BALB/c mice or
hamsters, respectively. BALB/c mice and hamsters were
purchased from Jackson Laboratories, Bar Harbor, ME and from
Charles River Laboratories, Wilmington, MA, respectively.
Sporozoites were collected by dissecting the mosquito salivary
glands in medium 199, - 2 weeks after the infective blood meal.
Female BALB/c mice aged 4 - 8 weeks were used for the
immunological studies. Mice were challenged intravenously with
the indicated dose of viable sporozoites. Their parasitemia was
monitored daily by peripheral blood smears obtained from the
3rd to the 10th day after challenge.
Peptides
Two peptides containing the CTL epitopes of the CS protein of
P. berghei (Pb 249-260 NDDSYIPSAEKI) and of P. yoelii (Py
277-288 NDESYVPSAEQI) were synthesized as described (3).
Cell culture
As culture medium we used DMEM - high glucose (Grand Island
Biological Co., Long Island, NY) supplemented with 0.2 g/l of
L-arginine (Calbiochem Co., La Jolla, CA), 0.036 g/l of L-
asparagine (GIBCO), 10 mM HEPES, 2 mM L-glutamine,
5 x 10-5 M 2-mercaptoethanol, 10% fetal calf serum (Hyclone,
Logan, Utah) and 1.5-2% of T cell growth factor medium,
derived from phorbol myristate-acetate activated EL-4 cells (7).
The cultures were maintained at 37°C in an atmosphere
containing 5% CO2.
Stimulation and cloning of the cytotoxic T lymphocytes (CTL)
Two BALB/c mice were injected four times, i.v., with 105
radiation-attenuated (15 x 103 rads) P. yoelii sporozoites, every
15 days. Two weeks after the last injection, immune spleen cells
were stimulated in culture with P815 cells, that had been pulsed
with peptide Py 277-288, as previously described (6). After the
third cycle of in vitro stimulation, cells were cloned, 0.5-1000
cells per well, in the presence of irradiated spleen cells and
peptide pulsed P815 cells, as previously described (8).
Cells were also cloned directly from immune spleen cells using
300 -10,000 spleen cells per well. Once established, the clones
(0.125 x 106 per ml) were re-stimulated weekly with irradiated
feeder cells (2.5 x106 per ml), and irradiated P815 cells
(1.25 x iO 5 per ml) pulsed with 1 /iM of either peptide Py
277 - 288 or Pb 249 - 260. Four days later, and after the addition
of an equal volume of medium, the cultures were divided and
grown under the same conditions for 2 - 3 more days.
Adoptive transfer of CTL clones
CTL clones were harvested 6 - 7 days after re-stimulation with
peptide-pulsed target cells and feeder cells. The desired number
of cells from the CTL clones or spleens were centrifuged and
resuspended in DMEM medium containing 2 x 103 units per ml
of human recombinant interieukin 2 (IL-2) (kindly provided by
Hoffmann-LaRoche), immediately before transfer. A total volume
of 0.5 ml of the cell suspension or IL-2 alone was injected i v.
into each mouse. All mice were challenged with sporozoites,
16 - 20 h after the cell transfer, unless otherwise indicated. These
mice also received 103 units of human recombinant IL-2, 1 day
after the challenge. In some experiments the mice were also
treated with mouse monoclonal antibody DB-1, which neutralizes
murine interferon gamma (IFN-y) (9), or hamster monoclonal
antibody TN3.19.12, anti-murine tumor necrosis factor (TNF) (10).
These antibodies were injected 2 h before the CTL clones. In
these experiments, the mice were challenged 5 - 6 h after the
injection of the T cells.
Quantification of P. yoelii rRNA in the liver of infected mice
Total RNA was isolated from the livers of mice killed 42 h after
they had been injected with 2 x 105 sporozoites of P. yoelii. At
this time, i.e. 42 h after challenge, the intra-hepatocytic parasites
(schizonts) have undergone maximal nuclear division and growth.
The sporozoite dose was selected based on the finding that it
consistently generates a strong signal, permitting the measure-
ment of P. yoelii rRNA in the livers of control animals (11). Details
of the method of isolation of RNA, the composition of the
oligonucleotide probes specific for P. yoelii ribosomal RNA, and
the hybridization procedure have been described elsewhere (11).
Briefly, RNA was prepared by the method of Chomczynski and
Sacchi (12). One-tenth of the whole liver RNA was precipitated
with isopropanol. The RNA pellet was dissolved in 10 mM
Tris - HCI pH 8.0,1 mM EDTA, denatured at 65°C in 20 x SSC
(1 xSSC contains 150 mM NaCI, 15 mM Na citrate):37%
formaldehyde (1:1). This solution was diluted 45 times and 0.2 ml
were blotted onto nylon membranes. The RNA was fixed to the
filters by UV crosslinking. Hybridization was performed overnight
in 5 xSSPE (1 xSSPE contains 180 mM NaCI, 10 mM Na
phosphate, 1 mM EDTA, pH 7.7), 1 % sodium dodecyl sulfate
(SDS) and 500 /tg/ml heparin at 42°C, containing several
oligonucleotide probes labeled with ^P (106 c.p.m./ml; specific
activity >2x10 8 c.p.m.//xg). Filters were washed twice in
6 xSSC + 0.1% SDS and once with 1 xSSC + SDS, at room
temperature for 15 min. The membranes were dried, the spots
on the filters were cut out and the radioactivity measured in a
liquid scintillation counter. A standard curve, for comparison
purposes, was prepared using purified RNA from P. yoelii
infected erythrocytes, and blotted under the same conditions.
The minimum amount of rRNA that this assay can detect is 1 ng
per sample.
Chromium release assay
For this in vitro cytotoxicity assay we used P815, a histo-
compatible (H-2^ cell line, standardly used as target cell,
labelled with 250 ^Ci of 51Cr (ICN Biomedicals, Irvine, CA). After
washing, 2 x 103 cells per well were cultured with 104 CTL, in
the presence of the desired concentration of the peptide of
choice. After 4 h at 37°C, the supernatants were collected with
the aid of a semi-automatic harvester (Skatron, Sterling, VA). The
results are expressed as the mean values obtained from duplicate
cultures. The percentage of specific lysis was calculated as
follows: experimental - spontaneous release c.p.m./total -
spontaneous release x100.
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Fig. 1. Specificity of the in vitro lytc activity of CD8+ anti-CS clones. CTL clones (YB8, YA15, YA23 and YA26), generated by immunization with
irradiated P yoeiii sporozoites (panels A - D) or P. berghet sporozoites (clone CS C7, panel E) were incubated with 51Cr-labelled P815 target cells,
in the presence of various concentrations of the P. yoeiii peptide 277-288 ( • ) or P. berghei peptide 246-260 (O). The effector to target ratio
(E/T) used in these experiments was 5:1. The release of 51Cr was measured after 4 h of incubation.
Results
Cytotoxic anti-P. yoeiii CD8+ T cell clones protect against a
challenge with P. yoeiii sporozoites
Five CTL lines were obtained after cloning cells from one immune
spleen (YA) that had been stimulated in mass culture for three
weekly cycles: YA11, YA15, YA20, YA23, and YA26. Two others
(YA2 and YB8) were cloned directly from immune spleen cells,
i.e. without first undergoing in vitro stimulation. All these CTL
clones recognize a synthetic peptide comprising the amino acid
sequence 277 - 288 of the P. yoeiii CS protein. As shown in Fig. 1
(A to D), these CTL clones lyse the target cells in the presence
of the P. yoeiii peptide 277-288, but do not recognize the
cytotoxic epitope of P. berghei (peptide 249 - 260). In contrast,
the CTL clone CS.C7 (3), derived from P. berghei immunized
mice, recognizes the P. berghei CTL epitope and also displays
a low, but significant, cross-reactivity with the P. yoeiii epitope
(Fig. 1E). All these clones express CD3 and CD8, but not CD4
surface markers and are restricted by H-2kd (6).
To investigate the in vivo anti-plasmodial activity of the CD8+
T cell clones, a series of adoptive transfer experiments were
performed in naive mice which, 20 h later, were challenged with
Table 1 . Effect of adoptive transfer of CTL clones on the outcome
of a challenge with Plasmodium yoeiii sporozoites
CTL clone
transferred
YA23
YA26
YB8
YA15
Spleen ceils
YA26
None
No. of cells
(x10«)
32
32
28
90
31
25-30
-
Protected mice/
total challenged8
5/5
5/5
0/5
0/3
0/5
7/10
0/10
Percentage
of protection
100
100
0
0
0
70
0
"All mice were challenged i.v. with 100 P. yoeiii sporozoites. The
protected animals remained negative, while all the control mice developed
parasitemia.
viable P. yoeiii sporozoites. As shown in Table 1, all the mice
which received the cytotoxic clones YA23 and YA26 were
protected, i.e. failed to develop parasitemia after sporozoite
challenge. In contrast, adoptive transfer of CTL clones YB8 and
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YA15, which appear to have the same epitope specificity as YA23
and YA26, failed to confer protection, even when as many as
9 x 107 cells of clone YA15 were transferred to each mouse.
The protection conferred by clones YA23 and YA26 did
depend on the size of the sporozoite challenge. Protection was
consistently achieved when the mice were challenged with 100
P. yoelii sporozoites, which resulted in 100% infection in the
control group. The number of sporozoites used for challenge
represents five times the minimum dose required to achieve
infection of 100% of normal BALB/c mice (data not shown). When
the challenge dose consisted of 1000 or more sporozoites, the
experimental animals were no longer protected. They developed
parasitemia, usually 1 day later than the controls (data not shown).
When blood stages of P. yoelii were used to challenge the mice
which had received the clone YA26, no inhibition of parasite
development occurred, indicating that the protective activity of
the CTL clones is stage specific (data not shown).
While the protective CTL clones inhibited parasite development
when transferred into mice 20 h before their challenge with
sporozoites, we observed a similar degree of protection when
the CTL were transferred after sporozoite invasion of the
hepatocytes has taken place (13). As seen in Table 2, when the
anti-P. yoelii clone (YA26) was transferred 3 h after challenge
with P. yoelii sporozoites, it conferred full protection to 73% of
the mice. This same clone, transferred 20 h before challenge,
conferred protection to 80% of the mice. Similar results were
obtained with the anti-P. berghei CTL clone, CS.C7, which pro-
tected all the mice, regardless of whether it was transferred before
or after sporozoite challenge (Table 2).
Species-specificity of the protection mediated by anti-P. yoelii and
anti-P. berghei CTL clones
The in vitro results did indicate that the CTL clones YB8, YA15,
YA23, and YA26 (anti-P. yoelii) do not recognize the P. berghei
epitope (Fig. 1A - D). As for the protective anti-P. berghei clone,
CS.C7, it displays in vitro, a weak cross-reactivity with the P. yoelii
epitope (Fig. 1E).
To characterize further the species-specificity of the protection
mediated by the anti-P. yoelii CTL clones, we performed a series
of cross-protection experiments. When the CTL done YA26 (anti-
P. yoelii) was transferred to mice and these were challenged with
P. yoelii sporozoites, 90% of the mice were protected, i.e. did
not develop parasitemia. In contrast, 80% of the mice which
received the same YA26 clone developed parasitemia after they
were challenged with P. berghei sporozoites (Table 3). Con-
versely, when mice were injected with the anti-P. berghei clone,
CS.C7, 100% protection was obtained in the group of mice
challenged with P. berghei sporozoites, while no protection was
observed when the challenge consisted of P. yoelii sporozoites
(Table 3). All control mice injected with P. yoelii and more than
90% of those infected with P. berghei sporozoites developed
parasitemia.
CTL clones inhibit the development of the liver stages of P. yoelii
To gain further and more quantitative insight into the inhibitory
effect of these CTL clones on the development of liver stages
of P. yoelii, we measured the amount of parasite-specific rRNA
present in the liver of mice which had received CTL clones and
were subsequently injected with P. yoelii sporozoites. The livers
of several mice were excised 42 h after sporozoite challenge and
the total RNA from each mouse liver was partially purified. The
amount of parasite rRNA was determined on the basis of a dot-
hybridization assay, using parasite-specific ribosomal
oligonucleotide probes, as described elsewhere (11).
We found that mice which had received 2.5 x 107 cells of the
protective clone YA26, and had been challenged with 2 x 10s
P. yoelii sporozoites, had very little or no detectable parasite rRNA
in their livers. In contrast, the levels of parasite rRNA present in
the livers of mice which had received the non-protective clone
YA15 were comparable to those present in control mice, injected
with parasites, but not with cytotoxic T cell clones (Fig. 2A).
Identical results were obtained when the transfer of CTL clones
was performed 20 h after sporozoite challenge (data not shown).
Noteworthy was the finding that mice injected with clone YB8,
considered to be non-protective on the basis of the parasitemia
which the mice developed after cell transfer and challenge
Table 2. Protective effect of the adoptive transfer of CTL clones
performed prior to and after sporozoite challenge
Table 3. Effect of the adoptive of CTL clones YA26 and CS.C7
on the outcome of challenge with either P. yoelii or P. berghei
sporozoites
CTL done
transferred
YA26
YA26
CS.C7
CS.C7
Hours before ( - )
or after (+)
challenge
- 2 0
+ 3
- 2 0
+ 3
Sporozoite
species
P. yoelii
P. yoelii
P. yoelii
P. berghei
P. berghei
P. berghei
Protected mice/
total challenged8
(% of protection)
8/10 (80)"
11/15(73)
0/10 (0)
10/10 (lOOp
9/9 (100)
1/12 (8)
CTL clones
transferred8
YA26
CS.C7
None
YA26
CS.C7
None
Sporozoite
challenge
P. yoelii
P. yoelii
P .yoelii
P. berghei
P. berghei
P. berghei
Protected mice/
total challenged13
9/10
0/10
0/5
4/20c
19/20
0/20
Percentage of
protection
90
0
0
20
95
0
were challenged with 100 sporozoites of P. yoelii or 104 of
P. berghei sporozoites. These doses represent five times the minimum
amount of sporozoites to produce patent parasitemia in BALB/c mice.
All P. yoelii controls and 11 of the 12 P. berghei control mice developed
patent infections. None of the 'protected' mice developed parasitemia
b0.5-2.5 x107T cells were transferred per mouse. Combined results
of two experiments.
C2 x 107 T cells were transferred per mouse.
a 2 - 4 x 1 0 7 of CTL clone YA26, and 2 - 3 x 1 0 7 cells of CTL clones
CS.C7 were transferred per mouse.
bAII mice were challenged with 100 P. yoelii or 104 P. berghei
sporozoites. These doses represent five times the minimum amount of
sporozoites to produce patent parasitemia in BALB/c mice. AO the control
mice developed patent infections, while the protected mice remained
negative.
°Combined results of four experiments.
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(Table 1), showed a 59% reduction of the amount of P. yoelii
rRNA in the liver. The adoptive transfer of CTL clone CS.B83,
which is specific for the P. berghei epitope and does not cross-
react in vitro with the P. yoelii epitope (3), did not have any signifi-
cant effect on the levels of P. yoelii rRNA (Fig. 2A).
We also tested the effect on P. yoelii of the CTL clone CS.C7
which in vivo is protective against P. berghei sporozoites. As
shown in Fig. 2B, the transfer of 2.5 x 107 cells results in partial
decrease (40%) of the liver stage rRNA of P. yoelii. This partial
inhibition may be due to the fact that CS.C7, differently from
CS.B83, recognizes not only the P. berghei but also the P. yoelii
peptide 277-288 in vitro (Fig. 1E). It is noteworthy that the
inhibitory effect of the cross-reactive clone CS.C7 is much less
efficient than the one mediated by the anti-P. yoelii clone YA26.
The later clone (YA26), reduced by 85% the parasite rRNA when
5 xiO6 , i.e. five times less cells, were transferred (Fig. 2B).
The capacity of clone YA26 to inhibit the development of liver
stages was found to be dose-dependent. Reduction of the rRNA
by 50% could be achieved after transferring as few as
2.5 x 106 cells, while none or very low levels of parasite rRNA
were consistently observed after the adoptive transfer of
3OT
1.2 x 107 of these cells. No inhibition of parasite development
was seen upon transfer of 1 x 10s cells of this clone (Rg. 3).
Antibodies against murine IFN-y and TNF fail to neutralize the
anti-plasmodial activity of these CD8+ T cell clones
Earlier studies had shown that IFN-7 has a potent inhibitory effect
on the development of the liver stages of malaria parasites (14).
Furthermore it has been reported that neutralizing anti-IFN-7
antibodies can reverse the immunity induced by immunization
with irradiated sporozoites (15). To determine whether IFN-y plays
an important role in the in vivo anti-liver stage activity of the CTL
clones, the neutralizing anti-IFN-7 monoclonal antibody DB-1 was
10OT
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Fig. 3. Dose dependence of the inhibitory activity of the CTL clone YA26
in vivo. Shown are the number of T cells adoptively transferred to naive
mice, 6 h before their infection with P. yoelii sporozoites. The percentage
inhibition was calculated in relation to the amount of parasite rRNA present
in the liver of control mice, challenged with sporozoites but not injected
with T cells. The bars represent the mean value obtained from three mice
± SE. 100% inhibition signifies that the sample contained less than 1 ng
of parasite rRNA.
CTL CLONE NONE
TRANSFERRED
YA26 YA26* CS.C7
Rg. 2. In vivo inhibition of liver stage development by adoptively
transferred CTL clones. 2.5 x 107 cells of various anti-P. yoelii (YA26,
YB8, and YA15) and anti-P. berghei (CS.B83 and CS.C7) CTL clones
were adoptively transferred to naive mice 6 h before challenge with
P. yoelii sporozoites. The amount of P. yoelii rRNA present in the liver
of infected mice was measured 42 h after challenge. The bars represent
the mean value obtained from three mice ± standard error of the mean
(SE). The asterisk at YA26, in B, indicates that 5 X106 cells were
transferred to each mouse. Absence of parasite rRNA, as determined
in this assay, means less than 1 ng in the sample.
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Fig. 4. Neutralizing antibodies to murine IFN-y and TNF fail to reverse
the in vivo inhibitory effect of a CTL clone. Monoclonal antibodies to murine
IFN-7 (0.5 mg/mouse) or TNF (0.3 mg/mouse) were injected into naive
mice, 2 h before they received the CTL clone YA26 (7.5 x 106 cells per
mouse). 6 h later, the animals were challenged with P. yoelii sporozoites.
The percentage inhibition was calculated as in Rg. 3.
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injected into mice, as previously described (15), prior to the
adoptive transfer of the CTL clone YA26. The dose of antibody
administered in different experiments ranged between 0.5 to
1.0 mg per mouse. As seen in Fig. 4, the degree of inhibition
of parasite development mediated just by the injection of clone
YA26 did not differ significantly from that seen in mice which had,
in addition, been injected with the IFN-y neutralizing antibody.
We were also unable to reverse the protective activity of clone
YA26 by injecting monoclonal antibody TN3.19.12(0.3-1.0mg
per mouse) which is specific for and inhibits the biological activity
of murine TNF in vivo (16). Furthermore, the inhibitory activity
of this CTL clone was not reversed when the mice simultaneously
received both of these monoclonal antibodies (data not shown).
Discussion
The present study demonstrates that adoptive transfer, into naive
mice, of certain CD8+ CTL clones which recognize a defined
epitope in the CS protein of P. yoelii, protects against sporozoite-
induced malaria. These results resemble those obtained earlier
in the P. berghei system (3), and thus confirm the more general
validity of the protective role of anti-CS CD8+ CTL in sporozoite-
induced rodent malaria.
The experiments described in the present report also
demonstrate that the anti-parasite activity of these protective T
cell clones is species specific. In fact, the results show that while
certain anti-P. berghei and anti-P. yoelii CD8+ clones confer a
high degrees of protection against sporozoites of the respective
species, the same clones induce no or only a small inhibitory
effect when the mice are challenged with sporozoites of the
heterologous species.
Still, it is noteworthy that parasitemia did not develop in 20%
of the mice which had received the anti-P. yoelii CTL done YA26
and were challenged with P. berghei sporozoites (Table 3). In
view of the fact that clone YA26 does not appear to cross-react
in vitro with a synthetic peptide containing the P. berghei epitope,
the partial cross-protection we observed suggests that this clone
may possibly mediate a certain 'non-specific' inhibition of liver
stage development. Alternatively, it is possible that clone YA26
cross-reacts in vivo with an epitope presented upon processing
by the parasitized liver cells, which may differ somewhat in size
and therefore in sequence from the peptide we used in the in vitro
assay (17,18).
The most likely targets of the inhibitory effects of these cytotoxic
T cells are the liver stages of the parasite. This view is based
on the high degree of protection observed upon transfer of
protective T cell clones 3 h after challenge, at a time when
sporozoite invasion of hepatocytes is certain to have been
completed (13). It is further corroborated by the fact that transfer
of these clones did not protect mice against a challenge with
blood stages of the same parasite. Furthermore, recent studies
have shown that sporozoite-immune spleen cells, stimulated with
a synthetic peptide comprising the P. yoelii 281 - 296 epitope,
inhibit the development of P. yoelii liver stages in cultured mouse
hepatocytes (5).
In the present report we demonstrate that the transfer of
protective cytotoxic clones greatly reduces the level of parasite
rRNA, thus providing direct evidence of the fact that these
CD8+ T cell clones inhibit, in a dose-dependent manner, the
in vivo development of the liver stages of this parasite. Significant
decrease of rRNA was seen upon transfer of only 2.5 x iO6
cells of the YA26 clone. This is noteworthy since only a fraction
of these cells reach the liver, most transferred cells being entrap-
ped in the lung. Migration studies performed during a 48-h period
with radiolabeled YA26 cells revealed that the amount of T cells
which migrate to the liver reaches a maximum 24 h after transfer
and represents 17.8 ± 5 .1% of the total amount of transferred
cells. The pattern of migration is not altered by a concurrent
sporozoite infection (manuscript in preparation).
The individual anti-P. yoelii CD8+ T cell clones we assayed
differed in their capacity to confer protection against a sporozoite
challenge, resembling our earlier observations in the P. berghei
system (3). These functional differences among CTL clones were
highlighted in experiments in which the protective effect of the
different clones was determined by measuring the parasite rRNA
in the liver of the challenged mice. Parasite rRNA was
undetectable (less than 1 ng per sample) and therefore reduced
by more than 20-fold in the livers of mice injected with the
protective clone YA26. The fact that parasite rRNA was not
detectable under these conditions cannot be interpreted as
indicating the complete absence of parasites in the liver, namely
that sterile immunity has been achieved. The lack of detection
of parasite rRNA under these conditions most likely reflects the
limit of sensitivity of the assay (11).
Mice injected with clone YA15 had parasite rRNA levels similar
to those found in control mice injected with sporozoites but not
with CTL clones. These results were unexpected, in view of the
results of the in vitro cytotoxic assays in which clone YA15 lysed
target cells as efficiently as clone YA26, and produced similar
or even larger amounts of IFN-7. These findings indicate that the
capacity of CTL clones to induce protection upon passive transfer
requires additional properties, besides in vitro cytotoxicity.
Based on earlier studies (19), mice which had been injected
with CTL clones, and their controls, were also injected with
recombinant IL-2. Experiments in which we measured P. yoelii
rRNA revealed that the administration of IL-2 did not alter the
protective nor the non-protective effects of the transfer of clones
YA26 and YA15, respectively (data not shown).
We are currently undertaking a detailed characterization of the
fine epitope-specificity of these clones, of their profile of
lymphokine production, and their patterns of migration and
homing in mice. This will, hopefully, clarify the basis of the
observed functional differences and cross-reactivities.
The mechanisms of the inhibitory activity of cytotoxic CD8+
T cell clones on the liver stages of malaria parasites has not yet
been identified. It is possible that these clones exert a direct
cytotoxic effect on the parasitized hepatocytes. Another possibility
is that this inhibitory effect may be mediated by lymphokines
produced locally by the CTL clones, after recognizing the
corresponding epitope on the surface membrane of antigen-
presenting cells (Kupffer cells or other mononuclear phagocytes).
It was reported earlier that IFN-7 and TNF inhibit the
development of plasmodial liver stages in vitro (14,20). In vivo
treatment of sporozoite-immunized A/J mice with anti-IFN-7
monoclonal antibody was reported to reverse protection against
P. berghei sporozoites (15). However, a similar treatment of
sporozoite-immunized BALB/c mice appears to have no
detectable effect (21). Our current results regarding the
unchanged in vivo anti-parasitic activity of these CTL clones, upon
administration of neutralizing anti-IFN-7 and anti-TNF antibodies,
suggest that systemic levels of these lymphokines may not play
a significant role in the inhibitory effector mechanisms. These
results do not rule out the possibility that these cytokines might
be produced and acting locally, in the micro-environment of the
CD8+ T cells and of the infected hepatocytes.
Taken together these results indicate that the rodent malarias
provide a rather unique experimental model for the investiga-
tion of the effector mechanisms by which CD8+ T cells can
prevent the development of non-viral intracellular pathogens. The
elucidation of these protective mechanisms should benefit
ongoing attempts to design an effective malaria vaccine.
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